Effectiveness and safety of topical amphotericin B in 30% dimethyl sulfoxide cream versus 30% dimethyl sulfoxide cream for nondermatophyte onychomycosis treatment: A pilot study

What Was Tested

The paper reports a study of DMSO (dimethyl sulfoxide, non-peptide solvent), published as a randomized controlled trial.

Methods This randomized controlled study was conducted between January 2019 and November 2020.

Patients diagnosed with nondermatophyte mold onychomycosis were randomly divided into two groups of ten patients each: one treated with amphotericin B cream and the other with the vehicle cream.

Who Took Part

The study group was 19 patients.

Results Ten patients each treated with amphotericin B cream and the vehicle cream were included in the study, but only nine patients in the vehicle cream group were available for follow up.

How the Study Was Run

The researchers set it up as a randomized and pilot study.

The patients were allocated by chance, so the DMSO (dimethyl sulfoxide, non-peptide solvent) group and the comparison group should start out alike.

It is described as a pilot, a small early test of whether a larger DMSO (dimethyl sulfoxide, non-peptide solvent) study would be practical.

What Was Measured

PubMed files the paper under topics including Administration, Topical, Amphotericin B, Antifungal Agents, Dimethyl Sulfoxide, Foot Dermatoses, Onychomycosis and Pilot Projects.

The authors tagged it with the keywords fungi.

What This Means in Plain Language

The paper is a randomized and pilot study of DMSO (dimethyl sulfoxide, non-peptide solvent) in 19 patients.

With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.

The publication is from 2022 (Indian journal of dermatology, venereology and leprology), a journal based in United States.

More context: the DMSO (dimethyl sulfoxide, non-peptide solvent) compound page, all human trials.